Daniel S. Lorrain, Chief Scientific Officer at Contineum Therapeutics, Inc. (CTNM), sold 4,170 shares at $13.06 ($55K) on 2026-05-01, disclosed to the SEC on 2026-05-01.
Scheduled sale ($55k) by Chief Scientific Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $13.06 | 3,870 | $51K | 92.4% |
| 2 | $13.84 | 300 | $4K | 7.6% |
| Total | $13.12 avg | 4,170 | $55K | 100% |
| Filing → |
| CTNM | SELL | 2026-06-01 | $55K | — | Filing → |
| CTNM | SELL | 2026-04-06 | $56K | — | Filing → |
| CTNM | SELL | 2026-03-02 | $63K | — | Filing → |